Information between 9th March 2026 - 28th May 2026
Note: This sample does not contain the most recent 2 weeks of information. Up to date samples can only be viewed by Subscribers.
Click here to view Subscription options.
| Division Votes |
|---|
|
10 Mar 2026 - Victims and Courts Bill - View Vote Context Lord Booth voted Aye - in line with the party majority and in line with the House One of 148 Conservative Aye votes vs 0 Conservative No votes Tally: Ayes - 216 Noes - 170 |
|
10 Mar 2026 - Victims and Courts Bill - View Vote Context Lord Booth voted Aye - in line with the party majority and in line with the House One of 160 Conservative Aye votes vs 0 Conservative No votes Tally: Ayes - 252 Noes - 171 |
|
10 Mar 2026 - Victims and Courts Bill - View Vote Context Lord Booth voted Aye - in line with the party majority and in line with the House One of 165 Conservative Aye votes vs 0 Conservative No votes Tally: Ayes - 257 Noes - 174 |
|
10 Mar 2026 - Victims and Courts Bill - View Vote Context Lord Booth voted Aye - in line with the party majority and in line with the House One of 172 Conservative Aye votes vs 0 Conservative No votes Tally: Ayes - 273 Noes - 180 |
|
9 Mar 2026 - Crime and Policing Bill - View Vote Context Lord Booth voted Aye - in line with the party majority and in line with the House One of 162 Conservative Aye votes vs 0 Conservative No votes Tally: Ayes - 200 Noes - 162 |
|
11 Mar 2026 - Crime and Policing Bill - View Vote Context Lord Booth voted Aye - in line with the party majority and in line with the House One of 149 Conservative Aye votes vs 1 Conservative No votes Tally: Ayes - 163 Noes - 153 |
|
11 Mar 2026 - Crime and Policing Bill - View Vote Context Lord Booth voted Aye - in line with the party majority and in line with the House One of 181 Conservative Aye votes vs 0 Conservative No votes Tally: Ayes - 215 Noes - 180 |
|
11 Mar 2026 - Crime and Policing Bill - View Vote Context Lord Booth voted Aye - in line with the party majority and in line with the House One of 178 Conservative Aye votes vs 0 Conservative No votes Tally: Ayes - 227 Noes - 221 |
|
16 Mar 2026 - Pension Schemes Bill - View Vote Context Lord Booth voted Aye - in line with the party majority and in line with the House One of 181 Conservative Aye votes vs 0 Conservative No votes Tally: Ayes - 198 Noes - 171 |
|
16 Mar 2026 - Pension Schemes Bill - View Vote Context Lord Booth voted Aye - in line with the party majority and in line with the House One of 182 Conservative Aye votes vs 0 Conservative No votes Tally: Ayes - 201 Noes - 177 |
|
18 Mar 2026 - Crime and Policing Bill - View Vote Context Lord Booth voted Aye - in line with the party majority and in line with the House One of 134 Conservative Aye votes vs 0 Conservative No votes Tally: Ayes - 220 Noes - 191 |
| Written Answers | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
|
Blood Cancer: Medical Treatments
Asked by: Lord Booth (Conservative - Life peer) Monday 27th April 2026 Question to the Department of Health and Social Care: To ask His Majesty's Government, further to the Written Answer by Baroness Merron on 11 March (HL15021), how many patients are treated for non-Hodgkin lymphoma by the NHS each year. Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care) The National Health Service provides a range of treatments for non-Hodgkin lymphoma, including chemotherapy as a first treatment, immunotherapy, radiotherapy, targeted therapies, and stem cell transplantation for eligible patients. Effectiveness of treatments is assessed by clinicians for individual patients using data on measures such as the responsiveness of the cancer to treatment, remission, overall survival, and quality of life. The most appropriate treatment depends on the type and stage of lymphoma and the patient’s individual circumstances, and decisions are made by specialist multidisciplinary teams. The National Institute for Health and Care Excellence (NICE) has evaluated and recommended several Chimeric Antigen Receptor T Cell (CAR-T) Therapy treatments for use within the Cancer Drugs Fund for the treatment of various cancers, including for large B-cell lymphoma a sub type of non-Hodgkin lymphoma, which are now available to NHS patients in line with NICE’s recommendations. In November 2025, NHS England published commissioning guidance to support the implementation of CAR-T therapies for blood cancer. Furthermore, the National Cancer Plan commits to ensuring rare cancer patients, including blood cancer, have improved access to targeted and personalised treatments where genomics identifies suitable options. The plan aims is to improve survival rates for rare cancers, including blood cancers by exploring novel procurement routes for diagnostics and treatments. Genomics will support the development of new treatments to improve outcomes for those with cancer. The following table shows, from latest data available, the number of patients treated for non-Hodkin lymphoma receiving radiotherapy, systemic anti-cancer treatment (SACT), and tumour resections for their tumour, each year from 2019 to 2022:
|
||||||||||
|
Blood Cancer: Immunotherapy
Asked by: Lord Booth (Conservative - Life peer) Monday 27th April 2026 Question to the Department of Health and Social Care: To ask His Majesty's Government what plans they have to increase the availability of CAR T-cell therapy for the treatment of non-Hodgkin lymphoma over the next five years. Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care) The National Health Service provides a range of treatments for non-Hodgkin lymphoma, including chemotherapy as a first treatment, immunotherapy, radiotherapy, targeted therapies, and stem cell transplantation for eligible patients. Effectiveness of treatments is assessed by clinicians for individual patients using data on measures such as the responsiveness of the cancer to treatment, remission, overall survival, and quality of life. The most appropriate treatment depends on the type and stage of lymphoma and the patient’s individual circumstances, and decisions are made by specialist multidisciplinary teams. The National Institute for Health and Care Excellence (NICE) has evaluated and recommended several Chimeric Antigen Receptor T Cell (CAR-T) Therapy treatments for use within the Cancer Drugs Fund for the treatment of various cancers, including for large B-cell lymphoma a sub type of non-Hodgkin lymphoma, which are now available to NHS patients in line with NICE’s recommendations. In November 2025, NHS England published commissioning guidance to support the implementation of CAR-T therapies for blood cancer. Furthermore, the National Cancer Plan commits to ensuring rare cancer patients, including blood cancer, have improved access to targeted and personalised treatments where genomics identifies suitable options. The plan aims is to improve survival rates for rare cancers, including blood cancers by exploring novel procurement routes for diagnostics and treatments. Genomics will support the development of new treatments to improve outcomes for those with cancer. The following table shows, from latest data available, the number of patients treated for non-Hodkin lymphoma receiving radiotherapy, systemic anti-cancer treatment (SACT), and tumour resections for their tumour, each year from 2019 to 2022:
|
||||||||||
|
Blood Cancer: Medical Treatments
Asked by: Lord Booth (Conservative - Life peer) Monday 27th April 2026 Question to the Department of Health and Social Care: To ask His Majesty's Government what treatments are available from the NHS for non-Hodgkin lymphoma; and what assessment have they made of the relative effectiveness of each treatment. Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care) The National Health Service provides a range of treatments for non-Hodgkin lymphoma, including chemotherapy as a first treatment, immunotherapy, radiotherapy, targeted therapies, and stem cell transplantation for eligible patients. Effectiveness of treatments is assessed by clinicians for individual patients using data on measures such as the responsiveness of the cancer to treatment, remission, overall survival, and quality of life. The most appropriate treatment depends on the type and stage of lymphoma and the patient’s individual circumstances, and decisions are made by specialist multidisciplinary teams. The National Institute for Health and Care Excellence (NICE) has evaluated and recommended several Chimeric Antigen Receptor T Cell (CAR-T) Therapy treatments for use within the Cancer Drugs Fund for the treatment of various cancers, including for large B-cell lymphoma a sub type of non-Hodgkin lymphoma, which are now available to NHS patients in line with NICE’s recommendations. In November 2025, NHS England published commissioning guidance to support the implementation of CAR-T therapies for blood cancer. Furthermore, the National Cancer Plan commits to ensuring rare cancer patients, including blood cancer, have improved access to targeted and personalised treatments where genomics identifies suitable options. The plan aims is to improve survival rates for rare cancers, including blood cancers by exploring novel procurement routes for diagnostics and treatments. Genomics will support the development of new treatments to improve outcomes for those with cancer. The following table shows, from latest data available, the number of patients treated for non-Hodkin lymphoma receiving radiotherapy, systemic anti-cancer treatment (SACT), and tumour resections for their tumour, each year from 2019 to 2022:
|
||||||||||
|
Cardiovascular Diseases: Semaglutide
Asked by: Lord Booth (Conservative - Life peer) Wednesday 29th April 2026 Question to the Department of Health and Social Care: To ask His Majesty's Government when they expect the NICE guidelines on semaglutide for patients with cardiovascular disease will be published; and what plans they have to ensure that the guidance is implemented by GPs. Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care) The National Institute for Health and Care Excellence (NICE) is the independent body responsible for developing authoritative, evidence-based recommendations for the National Health Service on whether new medicines represent a clinically and cost-effective use of resources. NICE published final draft guidance on 1 April that recommends semaglutide as an option for reducing the risk of major adverse cardiovascular events, such as cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke, in people with cardiovascular disease and overweight or obesity. NICE currently expects to publish final guidance in May 2026. If recommended in final NICE guidance, the NHS would be required to fund treatment within three months of publication. Integrated care boards are responsible for determining local delivery arrangements and for ensuring that clinicians are supported to prescribe in accordance with NICE recommendations. |
||||||||||
|
Blood Cancer: Immunotherapy
Asked by: Lord Booth (Conservative - Life peer) Wednesday 11th March 2026 Question to the Department of Health and Social Care: To ask His Majesty's Government how many patients per annum are expected to be treated by the NHS with Car-T cell therapy for Non-Hodgkin Lymphoma. Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care) The following table shows the number of patients treated per annum with CAR-T cell therapy for non-Hodgkin lymphoma, from 2023 to 2025, and in total:
|
| Select Committee Documents |
|---|
|
Tuesday 19th May 2026
Oral Evidence - Brainomix, and Scancell Innovation in the NHS: Personalised Medicine and AI - Science and Technology Committee Found: Tuesday 19 May 2026 11.30 am Watch the meeting Members present: Lord Mair (The Chair); Lord Berkeley; Lord Booth |
|
Tuesday 19th May 2026
Oral Evidence - Autolus Therapeutics, and Genomics Ltd Innovation in the NHS: Personalised Medicine and AI - Science and Technology Committee Found: Tuesday 19 May 2026 10.15 am Watch the meeting Members present: Lord Mair (The Chair); Lord Berkeley; Lord Booth |
|
Tuesday 21st April 2026
Oral Evidence - Our Future Health, and UK Biobank Innovation in the NHS: Personalised Medicine and AI - Science and Technology Committee Found: and AI Tuesday 21 April 2026 11.50 am Watch the meeting Members present: Lord Mair (The Chair); Lord Booth |
|
Tuesday 21st April 2026
Oral Evidence - Professor Dame Sue Hill Innovation in the NHS: Personalised Medicine and AI - Science and Technology Committee Found: and AI Tuesday 21 April 2026 10.15 am Watch the meeting Members present: Lord Mair (The Chair); Lord Booth |
|
Tuesday 14th April 2026
Oral Evidence - Professor Cathie Sudlow Innovation in the NHS: Personalised Medicine and AI - Science and Technology Committee Found: 14 April 2026 11.45 am Watch the meeting Members present: Lord Mair (The Chair); Lord Berkeley; Lord Booth |
|
Tuesday 14th April 2026
Oral Evidence - Professor Andrew Morris Innovation in the NHS: Personalised Medicine and AI - Science and Technology Committee Found: 14 April 2026 10.25 am Watch the meeting Members present: Lord Mair (The Chair); Lord Berkeley; Lord Booth |
|
Tuesday 24th March 2026
Oral Evidence - Professor Anneke Lucassen Innovation in the NHS: Personalised Medicine and AI - Science and Technology Committee Found: and AI Tuesday 24 March 2026 11.45 am Watch the meeting Members present: Lord Mair (The Chair); Lord Booth |
|
Tuesday 24th March 2026
Oral Evidence - Cell and Gene Therapy Catapult, and Medicines Discovery Catapult Innovation in the NHS: Personalised Medicine and AI - Science and Technology Committee Found: 24 March 2026 10.15 am Watch the meeting Members present: Lord Mair (The Chair); Lord Berkeley; Lord Booth |
|
Tuesday 17th March 2026
Oral Evidence - Genomics England Innovation in the NHS: Personalised Medicine and AI - Science and Technology Committee Found: medicine and AI Tuesday 17 March 2026 11 am Watch the meeting Members present: Lord Mair (The Chair); Lord Booth |
|
Tuesday 17th March 2026
Oral Evidence - Professor Florian Markowetz Innovation in the NHS: Personalised Medicine and AI - Science and Technology Committee Found: and AI Tuesday 17 March 2026 10:15 am Watch the meeting Members present: Lord Mair (The Chair); Lord Booth |
|
Tuesday 10th March 2026
Oral Evidence - Dr Robert Goldstone, and Professor Ewan Birney Innovation in the NHS: Personalised Medicine and AI - Science and Technology Committee Found: and AI Tuesday 10 March 2026 11.50 am Watch the meeting Members present: Lord Mair (The Chair); Lord Booth |
|
Tuesday 10th March 2026
Oral Evidence - Professor Sir Mark Caulfield Innovation in the NHS: Personalised Medicine and AI - Science and Technology Committee Found: and AI Tuesday 10 March 2026 10.15 am Watch the meeting Members present: Lord Mair (The Chair); Lord Booth |
| Calendar |
|---|
|
Tuesday 14th April 2026 10 a.m. Science and Technology Committee - Oral evidence Subject: Innovation in the NHS: personalised medicine and AI At 10:15am: Oral evidence Professor Andrew Morris At 11:15am: Oral evidence Professor Cathie Sudlow View calendar - Add to calendar |
|
Tuesday 21st April 2026 10:15 a.m. Science and Technology Committee - Oral evidence Subject: Innovation in the NHS: personalised medicine and AI At 10:15am: Oral evidence Professor Dame Sue Hill At 11:30am: Oral evidence Professor Raghib Ali OBE - CEO, Chief Investigator and Chief Medical Officer at Our Future Health Professor Sir Rory Collins FRS, FMedSci, FRCP - Chief Executive at UK Biobank View calendar - Add to calendar |
|
Tuesday 28th April 2026 10 a.m. Science and Technology Committee - Private Meeting View calendar - Add to calendar |
|
Tuesday 19th May 2026 10 a.m. Science and Technology Committee - Oral evidence Subject: Innovation in the NHS: personalised medicine and AI At 10:15am: Oral evidence Dr Christian Itin - Chief Executive Officer at Autolus Therapeutics Professor Peter Donnelly - Chief Executive Officer at Genomics Ltd At 11:15am: Oral evidence Dr Michalis Papadakis - Chief Executive Officer and Co-Founder at Brainomix Dr Phil L'Huillier - Chief Executive Officer at Scancell View calendar - Add to calendar |
|
Tuesday 17th March 2026 10 a.m. Science and Technology Committee - Oral evidence Subject: Innovation in the NHS: personalised medicine and AI At 10:15am: Oral evidence Professor Florian Markowetz At 11:15am: Oral evidence Rich Scott - CEO at Genomics England View calendar - Add to calendar |
|
Tuesday 24th March 2026 10 a.m. Science and Technology Committee - Oral evidence Subject: Innovation in the NHS: personalised medicine and AI At 10:15am: Oral evidence Matthew Durdy - CEO at Cell and Gene Therapy Catapult Chris Molloy - CEO at Medicines Discovery Catapult At 11:15am: Oral evidence Professor Anneke Lucassen View calendar - Add to calendar |
|
Tuesday 2nd June 2026 10 a.m. Science and Technology Committee - Oral evidence Subject: Innovation in the NHS: personalised medicine and AI At 10:15am: Oral evidence The Baroness Blackwood of North Oxford - Chair at Health Data Research Service (HDRS) Dr Melanie Ivarsson - Chief Executive Officer at Health Data Research Service (HDRS) View calendar - Add to calendar |
|
Tuesday 9th June 2026 10 a.m. Science and Technology Committee - Oral evidence Subject: Innovation in the NHS: personalised medicine and AI At 10:15am: Oral evidence Roland Sinker CBE - Former CEO at Cambridge University Hospitals Trust (2015-2025) At 11:15am: Oral evidence Professor Andrew Beggs - Professor of Cancer Genetics and Surgery at University of Birmingham Professor Mikael Sodergren - Clinical Associate Professor at Imperial College London View calendar - Add to calendar |
|
Tuesday 16th June 2026 10 a.m. Science and Technology Committee - Oral evidence Subject: Innovation in the NHS: personalised medicine and AI At 10:15am: Oral evidence Dr Stephen Harden - President at The Royal College of Radiologists (RCR) Dr Bernie Croal - President at The Royal College of Pathologists At 11:15am: Oral evidence Dr Pritesh Mistry - Fellow, Digital Technologies at The Kings Fund Professor Ben Bridgewater - Chief Executive Officer at Health Innovation Manchester View calendar - Add to calendar |